Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea

키워드

참고문헌 (60)

1. Miller WC, "A meta-analysis of the past 25years of weight loss research using diet, exercise or diet plus exercise intervention", Int J Obes Relat Metab Disord, 21, pp.941~947 (1997)
2. Onakpoya IJ, "Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions : a systematic review", BMC Med, 14, pp.191~ (2016)
3. "Controlled substance schedules"[URL]
4. Badman MK, "The gut and energy balance : visceral allies in the obesity wars", Science, 307, pp.1909~1914 (2005)
5. Beliveau V, "A high-resolution in vivo atlas of the human brain’s serotonin system", J Neurosci, 37, pp.120~128 (2017)
6. Gillette R, "Evolution and function in serotonergic systems", Integr Comp Biol, 46, pp.838~846 (2006)
7. Voigt JP, "Serotonin controlling feeding and satiety", Behav Brain Res, 277, pp.14~31 (2015)
8. Heisler LK, "Activation of central melanocortin pathways by fenfluramine", Science, 297, pp.609~611 (2002)
9. Lam DD, "Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors", Endocrinology, 149, pp.1323~1328 (2008)
10. Rowland NE, "Effect of serotonergic anorectics on food intake and induction of Fos in brain of mice with disruption of melanocortin 3 and", or 4 receptors, 2010, pp.97, 107~111
11. Rogers P, "Acute fenfluramine administration reduces neuropeptide Y concentrations in specific hypothalamic regions of the rat : possible implications for the anorectic effect of fenfluramine", Peptides, 12, pp.251~255 (1991)
12. Choi S, "Effects of chronic fenfluramine administration on hypothalamic neuropeptide mRNA expression", Brain Res, 1087, pp.83~86 (2006)
13. Heisler LK, "Serotonin reciprocally regulates melanocortin neurons to modulate food intake", Neuron, 51, pp.239~249 (2006)
14. Baggio LL, "Biology of incretins : GLP-1 and GIP", Gastroenterology, 132, pp.2131~2157 (2007)
15. Larsen PJ, "Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem", Neuroscience, 77, pp.257~270 (1997)
16. Nishizawa M, "The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein", J Auton Nerv Syst, 61, pp.149~154 (1996)
17. Kakei M, "Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons", Auton Neurosci, 102, pp.39~44 (2002)
18. Labouesse MA, "Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4", J Neuroendocrinol, 24, pp.1505~1516 (2012)
19. Secher A, "The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss", J Clin Invest, 124, pp.4473~4488 (2014)
20. Jelsing J, "Liraglutide : short-lived effect on gastric emptying : long lasting effects on body weight", Diabetes Obes Metab, 14, pp.531~538 (2012)
21. Wang XF, "Endogenous glucagon-like peptide-1 suppresses high-fat food intake by reducing synaptic drive onto mesolimbic dopamine neurons", Cell Rep, 12, pp.726~733 (2015)
22. Osaka T, "Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system", Peptides, 26, pp.1623~1631 (2005)
23. Lockie SH, "Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling", Diabetes, 61, pp.2753~2762 (2012)
24. Horowitz M, "Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes", Diabetes Res Clin Pract, 97, pp.258~266 (2012)
25. Smith SR, "Multicenter, placebo-controlled trial of lorcaserin for weight management", N Engl J Med, 363, pp.245~256 (2010)
26. Fidler MC, "A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults : the BLOSSOM trial", J Clin Endocrinol Metab, 96, pp.3067~3077 (2011)
27. O’Neil PM, "Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study", Obesity (Silver Spring), 20, pp.1426~1436 (2012)
28. Wadden TA, "Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss : the SCALE Maintenance randomized study", Int J Obes 2005, 37, pp.1443~1451 (2013)
29. Pi-Sunyer X, "A randomized, controlled trial of 3.0 mg of liraglutide in weight management", N Engl J Med, 373, pp.11~22 (2015)
30. Davies MJ, "Efficacy of liraglutide for weight loss among patients with type 2 diabetes : the SCALE Diabetes Randomized Clinical Trial", JAMA, 314, pp.687~699 (2015)
31. Blackman A, "Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial", Int J Obes (Lond), 40, pp.1310~1319 (2016)
32. O’Neil PM, "Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity : a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial", Lancet, 392, pp.637~649 (2018)
33. Pelletier G, "Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus", Neurosci Lett, 127, pp.96~98 (1991)
34. Tong Y, "Role of dopamine in the regulation of proopiomelanocortin(POMC)mRNA levels in the arcuate nucleus and pituitary gland of the female rat as studied by in situ hybridization", Brain Res Mol Brain Res, 15, pp.27~32 (1992)
35. Billes SK, "Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice", Neuropsychopharmacology, 32, pp.822~834 (2007)
36. Anderson JW, "Bupropion SR enhances weight loss : a 48-week doubleblind, placebo-controlled trial", Obes Res, 10, pp.633~641 (2002)
37. Holtzman SG, "Suppression of appetitive behavior in the rat by naloxone : lack of effect of prior morphine dependence", Life Sci, 24, pp.219~226 (1979)
38. Atkinson RL, "Effects of long-term therapy with naltrexone on body weight in obesity", Clin Pharmacol Ther, 38, pp.419~422 (1985)
39. Spiegel TA, "Effect of naltrexone on food intake, hunger, and satiety in obese men", Physiol Behav, 40, pp.135~141 (1987)
40. Greenway FL, "Rational design of a combination medication for the treatment of obesity", Obesity(Silver Spring), 17, pp.30~39 (2009)
41. Greenway FL, "Effect of naltrexone plus bupropion on weight loss in overweight and obese adults(COR-I) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 376, pp.595~605 (2010)
42. Wadden TA, "Weight loss with naltrexone SR", bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial, 2011, pp.19, 110~120
43. Apovian CM, "A randomized, phase 3 trial of naltrexone SR", bupropion SR on weight and obesity-related risk factors(COR-II), 2013, pp.21, 935~943
44. Hollander P, "Effects of naltrexone sustained-release", bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes, 2013, pp.36, 4022~4029
45. Gentilella R, "Glucagon-like peptide-1receptor agonists in type 2 diabetes treatment : are they all the same", Diabetes Metab Res Rev, 35, pp.e3070~ (2019)
46. Meier JJ, "GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus", Nat Rev Endocrinol, 8, pp.728~742 (2012)
47. Kastin AJ, "Interactions of glucagon-like peptide-1(GLP-1)with the blood-brain barrier", J Mol Neurosci, 18, pp.7~14 (2002)
48. Hunter K, "Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis", BMC Neurosci, 13, pp.33~ (2012)
49. Davies M, "Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2diabetes : a randomized clinical trial", JAMA, 318, pp.1460~1470 (2017)
50. Hennekens CH, "Schizophrenia and increased risks of cardiovascular disease", Am Heart J, 150, pp.1115~1121 (2005)
51. Maayan L, "Management of antipsychotic-related weight gain", Expert Rev Neurother, 10, pp.1175~1200 (2010)
52. Larsen JR, "Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-or olanzapine-treated patients with schizophrenia spectrum disorder : a randomized clinical trial", JAMA Psychiatry, 74, pp.719~728 (2017)
53. Ganguly S, "Metabolic bariatric surgery and type 2 diabetes mellitus : an endocrinologist’s perspective", J Biomed Res, 29, pp.105~111 (2015)
54. Pajecki D, "Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery", Rev Col Bras Cir, 40, pp.191~195 (2013)
55. Gorgojo-Martínez JJ, "Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery", Surg Obes Relat Dis, 12, pp.1856~1863 (2016)
56. Danne T, "Liraglutide in an adolescent population with obesity : a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years", J Pediatr, 181, pp.146~153 (2017)
57. Macisaac RJ, "Intensive glucose control and cardiovascular outcomes in type 2 diabetes", Heart Lung Circ, 20, pp.647~654 (2011)
58. Bohula EA, "Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients(CAMELLIA-TIMI 61) : a randomised, placebo-controlled trial", Lancet, 392, pp.2269~2279 (2018)
59. Nissen SE, "Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors : a randomized clinical trial", JAMA, 315, pp.990~1004 (2016)
60. Marso SP, "Liraglutide and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 375, pp.311~322 (2016)

관련 논문AI추천